Inhibition of IgE-Production by Peroxisome Proliferator-Activated Receptor Ligands  by Rühl, Ralph et al.
ORIGINAL ARTICLE
Inhibition of IgE-Production by Peroxisome Proliferator-
Activated Receptor Ligands
Ralph Rˇhl,w Anja Dahten,w Florian J. Schweigert,w Udo Herz,z and MargittaWorm
Department of Dermatology and Allergy, ChariteŁ , Campus Mitte Medical School, Berlin, Germany; wInstitute of Nutritional Science, University of
Potsdam, Germany; zInstitute of Laboratory Medicine, University of Marburg, Germany
In this study we analyzed the e¡ect of peroxisome
proliferator-activated receptor-a and -c ligands on im-
munoglobulin synthesis and cytokine production in
non-allergic and atopic dermatitis donors in vitro, but
also in vivo ovalbumin-sensitized mice. A signi¢cant in-
hibition in CD40þ interleukin-4-mediated, but also
basal IgE synthesis from peripheral blood mononuclear
cells of atopic dermatitis donors was observed in
the presence of the peroxisome proliferator-activated
receptor-a ligand (up to 47712%) and peroxisome
proliferator-activated receptor-c ligand (6975%). By
contrast, the production of other isotypes such as IgA,
IgG, and IgM was only modest inhibited. Analysis of
cytokine production from the peripheral blood mono-
nuclear cells shows inhibition of several cytokines by
both peroxisome proliferator-activated receptor ligands.
The most inhibitory e¡ect on cytokine production was
observed by the peroxisome proliferator-activated re-
ceptor-c ligand in peripheral blood mononuclear cells
from atopic dermatitis donors with high IgE base-
line production. Coculture experiments show that the
decrease of IgE production by ciglitazone was mono-
cyte dependent (up to 6377%). Finally, in vivo experi-
ments from ovalbumin-sensitized mice con¢rmed
the in vitro ¢ndings showing that the interleukin-
4-mediated immune response was inhibited in ciglita-
zone-treated mice. Key words: atopic dermatitis/cytokines/
IgE/peroxisome proliferator-activated receptor ligands. J
Invest Dermatol 121:757 ^764, 2003
T
he peroxisome proliferator-activated receptors
(PPAR) are a family of transcription factors belong-
ing to the nuclear receptor superfamily. PPAR regu-
late a number of genes through ligand-dependent
transcriptional activation and repression, which plays
a regulatory role in several physiologic pathways such as lipid me-
tabolism, glucose regulation, and homeostasis in the skin (Lem-
berger et al, 1996; Kliewer et al, 2001;Wahli, 2002). Recent studies
suggested an immunoregulatory role of PPAR in macrophages
and monocytes, but recently also on lymphocyte function. It has
been shown that PPAR ligands inhibit T helper cell responses in
terms of inhibition of interleukin (IL)-2 production by T cell
clones, while not inhibiting proliferation of such clones (Clark
et al, 2000). Similarly, data from murine splenocytes showed that
PPARa and PPARg ligands decreased IL-2 and interferon (IFN)-
g production in mitogen-activated cells, but had modest e¡ects
on proliferation (Cunard et al, 2002). The advantage of the anti-
in£ammatory e¡ects of PPARg was demonstrated in murine
models of in£ammatory bowel disease (Su et al, 2000), but also
experimental allergic encephalitis (Niino et al, 2001).
In humans ciglitazone has been shown to be e¡ective in psor-
iasis a chronic in£ammatory skin disease (Ellis et al, 2000). Like
other receptors of the nuclear hormone-receptor superfamily
PPAR possess a central DNA binding domain that recognizes
PPAR response elements in the promoter regions of their target
genes. PPAR form heterodimers with the retinoid X receptors
(RXR) and the transcriptional regulation of target genes is
achieved by binding of these PPAR-RXR heterodimers.We have
recently shown that ligands of the nuclear hormone-receptor
superfamily like retinoids, but also vitamin D are potent inhibi-
tors of IgE production in vitro (Worm et al, 2001; Heine et al,
2002).
In this study we examined whether synthetic PPAR ligands
a¡ect immunoglobulin production in vitro and in vivo. Peripheral
blood mononuclear cells (PBMC) from nonallergic, but also
from atopic dermatitis (AD) patients characterized by high
spontaneous basal IgE production, were studied. Analysis of
the mechanisms involved in PPAR ligand action shows a
downregulation of several cytokines from PBMC of both
groups. These ¢ndings were con¢rmed by in vivo experiments
from ovalbumin-sensitized mice. Finally, cell coculture experi-
ments show that monocytes play a central part in the observed
inhibition of IgE production by the PPARg ligand.
MATERIALS ANDMETHODS
Cell preparation PBMC were isolated from bu¡y coats of nonallergic
healthy donors and AD patients by Ficoll Hypaque (D¼1.077; Biochrom
KG, Berlin, Germany) separation (350 g, 30 min, room temperature). All
AD patients ful¢lled the criteria of Hani¢n and Rajka, su¡ered from
moderate to severe AD and were sensitized against pollen, house dust
mite, and cat dander proven by skin prick test and speci¢c IgE levels
ranging from 0.35 to 100 kU per liter. Total serum IgE levels from the
patients ranged from 500 to 2000 kU per liter. None of the patients
received a systemic immunosuppressive medication of ultraviolet therapy
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at least 4 wk before the blood was drawn. Healthy subjects were de¢ned as
individuals who have not experienced allergic symptoms by history, had
IgE levels below 0.5 U per mL, and no history of atopic eczema. The use
of topical steroids (class II^III) or antihistamines were not considered
exclusion criteria.
B cells were puri¢ed by magnetic cell sorting using anti-CD19-coupled
magnetic beads (Miltenyi Biotec, Bergisch-Gladbach, Germany). Brie£y,
4108 PBMC in 800 mL phosphate-bu¡ered saline (PBS)þ 20 nM
ethylenediamine tetraacetic acidþ 0.2% bovine serum albumin, and 15 mL
Beriglobin (Chiron Behring, Marburg, Germany) were incubated for
10 min on ice, followed by addition of 200 mL conjugated beads (1:5 ratio)
and a 10 min incubation at 41C. After several washings, CD19-positive B
cells were separated by magnetic positive selection with LSþ columns
(Miltenyi Biotec), and the cells were then resuspended in medium
and counted. The puri¢ed cell population contained more than 95% B
cells, as assessed by immuno£uorescence with anti-CD20 £uorescein
isothiocyanate (FITC) conjugated antibody. The same procedure was done
for the puri¢cation of T cells and monocytes, respectively, using anti-CD3
and anti-CD14 coupled magnetic beads (Miltenyi Biotec). For the
coculture experiments the ratio between the di¡erent cell types was 1:1.
Cell culture PBMC and puri¢ed B cells (106 cells per mL) were cultured
in RPMI 1640 culture medium supplemented with L-glutamine (2 mM),
penicillin (100 U per mL), streptomycin (100 mg per mL), and 10% heat
inactivated fetal calf serum (all from Biochrom Berlin, Germany). All cell
cultures were carried out at 371C in humidi¢ed air and 5% CO2
atmosphere.
Reagents IL-4 was purchased from R&D (Wiesbaden, Germany),
puri¢ed anti-CD40 monoclonal antibody (MoAb) (clone 626.1) was a
kind gift from R. Geha (Children’s Hospital, Boston, Massachusetts). The
PPARa ligand was synthesized as described previously (Brown et al,
1999) and the PPARg ligand was purchased from Alexis Biochemicals
(Grˇnberg, Germany).
WST-1 assay For studies of B cell mitochondrial activity, the WST-1
assay was used (Boehringer Mannheim, Germany). Brie£y, 105 cells were
cultured for 4 d and 10 mLWST-1-reagent was added during the last 3 h
of culture to each well. Cellular enzymatic activity was determined by
measuring optical densities with a photometer at 450 nm, and its OD
ranged from 0.10 to 0.473. Phorbol myristate acetate (10 ng per mL) was
used as a positive control, with an OD of 170.2. All experiments were
done in duplicate and data expressed as arithmetic means.
Immunoglobulin production Cells were cultured for 10 d, and
immunoglobulins were measured in the supernatants of stimulated cells
by enzyme-linked immunosorbent assay (ELISA). The MoAb for IgE
detection (clones HP 6061 and HP 6029) were kindly provided by Robert
Hamilton, Asthma and Allergy Center, Johns Hopkins University,
Baltimore, Maryland. The MoAb for IgA, IgG and IgM detection were
purchased from Dianova (Hamburg, Germany).
For the immunoglobulin assays, immunoplates (Nunc, Wiesbaden,
Germany) were coated overnight at 41C with the isotype speci¢c anti-
human Ig-Fc antibodies diluted in 0.1 M bicarbonate bu¡er. Blocking was
performed by adding 2% bovine serum albumin/Tris-bu¡erd saline for
1 h, followed by several washings. Supernatants and internal standards
were then added to the wells and incubated in duplicate for 2 h. After
several washes, the alkaline phosphatase-conjugated antibodies (IgA, IgG,
and IgM) or biotinylated anti-IgE MoAb was added. For IgE, plates were
incubated for another hour with alkaline phosphatase-conjugated
streptavidin. Following the ¢nal reaction with phosphatase substrate
(Sigma, Dreieich, Germany), plates were read in a microplate ELISA
reader at 405 nm, and the amount of immunoglobulin was calculated
according to the standard curve. The variations of readings in duplicate
cultures never exceeded 15%.
Cytokine ELISA The tumor necrosis factor-a, IL-2, and IL-4 ELISA
(Endogen,Woburn, Massachusetts), IFN-g ELISA (Genzyme, Cambridge,
Massachusetts), and IL-6 ELISA (BD, Heidelberg, Germany) were
performed according to the manufacturer’s instructions.
Animals Female mice (NMRI: Tierzucht Sch˛nwalde, Sch˛nwalde,
Germany) were kept under speci¢c pathogen-free conditions at 211C
711C, 5575% relative humidity, and 12 h light/dark cycle with light
between 8.00 a.m. and 8.00 p.m. They received a standard pellet diet
(Altromin 1324, Altromin, Lage, Germany) and tap water ad libitum.
Drug administration Twelve mice of each application group obtained
5 wk for every second day an oral application of ciglitazone (7 mg per kg
body weight per day) or an oral control application. Each of the appli-
cations were dissolved in 25% cremophore EL solution in distilled water.
Two, 3, and 4 wk after beginning of the applications six mice of each
group were injected (intraperitoneal) with 100 mL ovalbumin/aluminum
hydroxide solution in saline (10 mg ovalbumin adsorbed on 1.5 mg
aluminum hydroxide) or with saline as control (Worm et al, 2001). Five
weeks after beginning the treatment the mice were euthanized and
peripheral, blood, and the spleen were collected. The blood samples were
immediately centrifuged to obtain serum, which was then kept frozen at
^801C till further analysis. Total IgE and allergen-speci¢c IgG1 and IgG2a
antibody titers were measured by ELISA, as previously described (Worm
et al, 2001). For cell analysis and cell culture experiments the spleens were
immediately (maximum 2 h after animals death) prepared.
Flow cytometric analysis and cell culture of splenic mononuclear
cells Lymphocytes were harvested from the spleen by gently pressing
the tissue through a ¢ne Falcon nylon mesh sieve (100 mm) (BD
Pharmingen, San Diego, California) and washing the cell suspension with
PBS without Ca2þ/Mg2þ . The lymphocytes were counted and 1  106 to
5  106 cells were stained with £uorochrome-labeled MoAb. The cell
suspensions were mixed with 100 mL labeled MoAb and bu¡er (10%
bovine serum albumin in PBS) in a 1:200 dilution. A double color
staining using FITC and phycoerythrin (PE) was performed using the
following MoAb combinations: FITC-conjugated rat IgG2a, with PE-
conjugated rat IgG2a; FITC-conjugated rat anti-mouse CD8a (Ly-2) with
R-PE-conjugated rat anti-mouse CD4 (L3T4) and FITC-conjugated rat
anti-mouse CD3 molecular complex with R-PE-conjugated rat anti-
mouse CD45R/B220. All MoAb were purchased from BD PharMingen
(San Diego, California). After 20 min at 41C in darkness, the cells were
washed. The supernatant was removed and the pellet resuspended with
500 mL paraformaldehyde (2% in PBS) purchased from Sigma (Munich,
Germany). The ¢xed cells were kept at 41C until cytometric analysis. The
cells were acquired and analyzed using a £uorescence-activated cell sorter
with Cell quest 3.3 software (FACSort, Becton Dickinson, San Jose,
California). A gate was set to record 50,000 events using side light scatter
and forward light scatter (FSC) light scatter parameters these allowed the
identi¢cation of the morphologic cell populations. The lymphocytes were
gated again and analyzed using FL1/FSC and FL2/FSC parameters. The
FL1/FSC dot plot expressed FITC and the FL2/FSC expressed PE. For
each staining the appropriate isotype control was done to evaluate
nonspeci¢c staining.
Cytokine determinations 106 splenocytes were cultured unstimulated
or stimulated (20 ng phorbol myristate acetate per mL and 0.2 mM
ionomycin) for 48 h. Supernatants were collected and kept frozen (^801C)
until further analysis by ELISA. For detection of the cytokines (IL-4/IFN-
g) ELISA from R&D (Wiesbaden, Germany) was used according to the
manufacturer’s guidelines.
Statistics Wilcoxon’s signed rank test for matched pairs was performed to
compare the results within the donor group. Statistically signi¢cant
di¡erences were considered with p-values less than 0.05.
RESULTS
Inhibition of anti-CD40þ IL-4-mediated IgE production
by PPAR ligands in PBMC from nonallergic donors To
examine whether PPAR ligands a¡ect IgE production, we
¢rst examined IgE production in anti-CD40þ IL-4 stimulated
PBMC from nonallergic donors. As shown in Fig 1(A), the
PPARa ligand signi¢cantly inhibited IgE production of anti-
CD40þ IL-4-stimulated cells in a concentration-dependent
manner. The maximum of inhibition was observed at 10^6 M
reaching 81711%. As shown in Fig 1(B), also the PPARg
ligand inhibited anti-CD40þ IL-4-mediated IgE synthesis
signi¢cantly (8378%) at the highest concentration used (2
10^5 M). Experiments in which di¡erent concentrations of the
PPAR ligands were used (10^910^6 M), indicated that IgE
production was not signi¢cantly inhibited at concentrations
below 1 mM (data not shown) of each ligand.
We studied next the mitochondrial activity of PBMC in the
presence of GW9578 and ciglitazone to rule out anti-
proliferative e¡ects of the PPAR ligands. Figure 2 shows
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that GW9578 had a negligible e¡ect on anti-CD40þ
IL-4-stimulated PBMC. By contrast, ciglitazone (410^5 M)
induced a modest, but signi¢cant reduction of mitochondrial
activity (1475%). Furthermore, highly puri¢ed B cells were
also studied in the presence of the PPAR ligands after anti-
CD40þ IL-4 stimulation. The data show that neither GW9578
nor ciglitazone inhibited anti-CD40þ IL-4-mediated cell
activation (data not shown). These ¢ndings indicate that the
observed e¡ects on IgE production were most likely not due to
reduced amounts of B cells or any cytotoxic e¡ects. This
observation was con¢rmed by trypan blue staining in which we
did not detect increased numbers of dead cells in the presence of
both PPAR ligands. Taken together these results demonstrate that
only anti-CD40þ IL-4-mediated IgE production but not cell
activation is inhibited by PPAR ligands in a concentration-
dependent manner.
Inhibition of basal IgE production by PPARa and PPARc
ligands in PBMC from AD donors We examined next
whether ongoing IgE production in previously switched B cells
is also inhibited by PPAR ligands. Therefore, we analyzed IgE
production in PBMC from patients with AD, which are
characterized by a spontaneous baseline IgE production if the
cells are cultured for 10 d (Frotscher et al, 2002).
As shown in Fig 3(A) the PPARa ligand GW9578 resulted in
a modest but not signi¢cant inhibition of IgE production in vitro.
By contrast, in the presence of ciglitazone basal IgE production
from AD donors was markedly and signi¢cantly reduced up to
6975% at 210^5 M (Fig 3B).
Inhibition of cytokine production by PPAR ligands It has
been demonstrated previously that PPAR ligands achieve their
immunomodulatory e¡ects through inhibition of cytokine
production. We examined therefore the production of several
cytokines in the presence of the PPARa and PPARg ligands.
Figure1. GW9578 (A) and ciglitazone (B) induced inhibition of IgE
production of anti-CD40þ IL-4-stimulated PBMC from six
healthy donors. Unstimulated PBMC (u.) or anti-CD40 (1 mg per
mL)þ IL-4 (5 ng per mL) stimulated cells were incubated for 10 d without
PPAR ligand as control (c.) or with GW9578 (10^8/10^6 M) or ciglitazone
(10^5/210^5 M). IgE, as detected in the supernatants by ELISA, was below
0.6 ng per mL in unstimulated cells and ranged from 1.7 to 23.3 ng per mL
after anti-CD40þ IL-4 stimulation. Inhibition of IgE production was sta-
tistically signi¢cant (po0.05). Mean values are expressed as black bars.
Figure 2. E¡ect of GW9578 (A) and ciglitazone (B) on anti-
CD40þ IL-4-mediated mitochondrial respiration. Human unstimu-
lated PBMC (black bars)þ anti-CD40 (1 mg per mL) and IL-4 (5 ng per
mL) stimulated cells (gray bars) were incubated without PPAR ligands
[control] or with GW9578 (10^8/10^6M) or ciglitazone (10^5/210^5 M).
Cells (106 per mL) were cultured for 4 d and 10 mL of WST-1 reagent was
added for the last 3 h. The reaction was measured photometrically at
450 nm. All experiments were done in duplicate, and data are expressed as
arithmetic means. Anti-CD40þ IL-4 stimulated, cells were set at 100%.
Mean7SEM are shown from six di¡erent donors.
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As shown in Fig 4 GW9578 inhibited the production of tumor
necrosis factor-a, IL-2, IFN-g, and IL-6 weakly (median
inhibition: 8%, 8%, 11%, 12%, respectively), but was
statistically signi¢cant in NA donors. By contrast, a statistically
signi¢cant cytokine inhibition by GW9578 in AD patients was
only observed regarding tumor necrosis factor-a (Fig 4D) and
IFN-g (Fig 4E) production (7% and 5%, respectively). By
contrast, ciglitazone resulted in a more pronounced inhibition
of all studied cytokines. The inhibition reached up to: (1) 14% in
the NA and 32% AD for tumor necrosis factor-a; (2) 32% NA
and 44% AD for IL-2; and (3) 25% NA and 38% AD for IFN-g.
The inhibitory e¡ects of ciglitazone on T helper 1-like cytokine
production were stronger in the AD than in the NA group.
Regarding the production of IL-4 (Fig 4A) and IL-6
(Fig 4B), a strong and signi¢cant inhibition by ciglitazone was
observed in both groups. The inhibition of ciglitazone was
higher in the AD group compared with NA reaching 29%
(NA) and 57% (AD) for IL-4, and 28% (NA) and 64% (AD)
for IL-6. Taken together the data suggest that mainly the
PPARg ligand ciglitazone inhibits the production of several
cytokines, which is more prominent in PBMC from AD donors.
Inhibition of IgE production is monocyte dependent The
inhibitory e¡ects by PPAR ligands on IgE production were
detected in cultured PBMC. Next we addressed the question of
which cell type might be responsible for these observed e¡ects.
Therefore, cells were puri¢ed by magnetic cell sorting and
coculture experiments were performed. The data show that the
inhibitory e¡ects of the PPARg ligand on IgE production were
modest when puri¢ed B cells were used (Fig 5A). By contrast, in
the presence of GW9578 no inhibition, but rather an enhanced
IgE synthesis was observed in anti-CD40þ IL-4-stimulated
human peripheral B cells.
In the presence of monocytes, however, a strong and
signi¢cant inhibition of IgE production was observed by
ciglitazone at 210^5 M (Fig 5B), but not GW9578. These
¢ndings suggest an important role of monocytes for the
observed e¡ects on IgE production at least by PPARg ligand in
anti-CD40þ IL-4-stimulated cells. Addition of IL-6 (5 ng per
mL) abolished the observed inhibition of IgE production (data
not shown), indicating that diminished IL-6 production through
ciglitazone is probably involved in the observed inhibition of IgE
production.
Ciglitazone inhibits modestly the production of other
isotypes To analyze the isotype speci¢city for IgE regarding
its inhibition by PPAR ligands, we have measured IgA, IgG,
and IgM synthesis in PBMC in the presence of di¡erent
concentrations of the PPAR ligands as well. As shown in Fig 6,
the secretion of IgA, IgG, and IgM are indeed modestly decreased
in a concentration-dependent manner by ciglitazone (in median
values: IgA from 60 to 24 ng per mL, IgG from 25 to 13 ng per
mL, and IgM from 7 to 4 ng per mL), but not GW9578 (data not
shown); however, the comparison of immunoglobulin inhibition
by ciglitazone between the di¡erent isotypes shows that only IgE
production was inhibited signi¢cantly.
Inhibition of IgG1 and enhancement of IgG2a production
in ovalbumin-sensitized mice by ciglitazone In order to
evaluate whether the observed e¡ects on IgE production by
ciglitazone in vitro are also relevant in vivo we studied immu-
noglobulin production in ovalbumin-sensitized mice that were
treated with ciglitazone (Table I). The total serum IgE was low
in nonsensitized control and ciglitazone-treated mice, respec-
tively (14.378 and 10.075 ng per mL) and enhanced in
ovalbumin-treated mice (32.3715 ng per mL). In the ovalbumin
sensitized and with ciglitazone-treated mice the total serum IgE
was signi¢cantly lower (8.274 ng per mL). As the used NMRI
mice belong to a low IgE responder strain we were not able to
detect ovalbumin-speci¢c IgE. The analysis of speci¢c IgG1/
IgG2a production shows, however, that in ovalbumin-sensitized
and ciglitazone-treated mice ovalbumin-speci¢c IgG1 produc-
tion was signi¢cantly decreased compared with the untreated
group (711.47127 and 3667139 mg per mL). By contrast, the
ovalbumin-speci¢c IgG2a response was signi¢cantly enhanced
in these mice (62367356 vs 36117323 LU per mL). These
data suggest a modulation of the allergic immune response
by ciglitazone in ovalbumin-sensitized mice and con¢rm our in
vitro data.
The analysis of lymphocyte counts of splenic cells in untreated
and ciglitazone-treated mice show comparable results between
the groups regarding CD8/CD4/B220 counts supporting the
¢nding of immune modulation rather than immunosuppression
by ciglitazone treatment (data not shown). The measurement of
IL-4 and IFN-g production of spleen cells shows (Table II) an
increased IL-4 and IFN-g production in ovalbumin-sensitized
mice. By contrast, mice that were treated with ciglitazone
showed a signi¢cantly decreased cytokine response (IL-4: 20.47
7.4 and 10.179.5; IFN-g: 19087172 and 13847403). Ciglitazone-
treated mice showed comparable IFN-g production with the
control mice (13227366 and 16037626) and a slightly increased
IL-4 response (9.779.2 and 16.479.3).
DISCUSSION
We demonstrate that the PPARa ligand and, to a greater extent,
the PPARg ligand inhibit IgE production but also the produc-
tion of other isotypes in vitro and in vivo. Coculture experiments
Figure 3. Inhibition of baseline IgE production of PBMC from
¢ve AD donors by GW9578 (A) and ciglitazone (B). Experiments
were performed as described in Fig 1.
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of B cells and monocytes showed that the PPAR ligand-asso-
ciated inhibition of IgE production is not directly mediated
through activated B lymphocytes, but rather primarily indirectly
mediated via regulatory signal pathways of monocytes. The
analysis of supernatants from PBMC in the presence of PPAR
ligands reveals that inhibition of IgE synthesis is most likely
related to the reduced secretion of several cytokines; however,
if we analyze the e¡ects in more detail our data show that the
PPARg ligand inhibits more prominently the production of cy-
tokines, such as IL-4 and IL-6, which are known to promote IgE
synthesis. Anti-in£ammatory e¡ects of ciglitazone were initially
demonstrated in murine models of in£ammatory bowel disease
Figure 4. Inhibition of cytokine production in
stimulated PBMC from ¢ve healthy and ¢ve
AD donors by GW9578 and ciglitazone. PBMC
(2106) were stimulated with phorbol myristate acet-
ate (20 ng per mL) and in the presence of either
GW9578 (10^6 M) or ciglitazone (210^5 M) as indi-
cated and cultured for 72 h. ELISA were performed
with the supernatants measured in duplicate. Statisti-
cally signi¢cant di¡erences (po0.05) based onWilcox-
on’s signed rank test are marked by an asterisk ().
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(Su et al, 2000), and experimental allergic encephalitis (Niino et al,
2001). In humans ciglitazone has been shown to be e¡ective in
psoriasis, which like AD is a chronic in£ammatory skin disease.
PPARg ligands have been shown to inhibit T helper cell re-
sponses in terms of inhibition of IL-2 production byTcell clones
(Clark et al, 2000). Data from murine splenocytes showed that
PPARa and PPARg ligands decreased IL-2 and IFN-g produc-
tion in mitogen-activated cells (Cunard et al, 2002).
In this study we did not ¢nd signi¢cant e¡ects on PBMC cell
proliferation indicated by stable mitochondrial cell activity in the
presence of the PPARa or PPARg ligand. This is in line with
data from other studies showing that PPARg ligands do not
inhibit the proliferation of T cell clones (Clark et al, 2000).
Similarly, data from murine splenocytes showed that PPARa
and PPARg ligands had only modest e¡ects on proliferation (Cu-
nard et al, 2002).
The e¡ect on ciglitazone in an allergy mouse model has not
been studied until to date. In a previous study by Su et al (2000),
Figure 5. Inhibition of IgE production by PPARc ligand ciglita-
zone is monocyte dependent. Cells (CD19 and CD14) were puri¢ed
by magnetic cell sorting. Highly puri¢ed B cells (A) and B
cellsþmonocytes (B), each 106 cells per mL, were incubated with or with-
out ciglitazone (control) in the presence of anti-CD40 (1 mg per mL)þ IL-
4 (5 ng per mL) for 10 d. IgE analysis was performed as described in Fig 1.
Figure 6. E¡ects of ciglitazone on IgA (A), IgM (B), and IgG (C)
production. Human unstimulated PBMC (1106) from three AD donors
were cultured for 10 d with and without ciglitazone (10^7/10^6/10^5/2
10^5 M). The immunoglobulins were detected in the supernatants by ELI-
SA. Mean values are expressed as black bars.
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the anti-in£ammatory e¡ect of PPARg ligands on colonic
epithelial cells was studied. Data from this study showed that
PPARg ligands attenuate cytokine gene expression by inhibiting
NF-kB activation via an IkB-dependent mechanism.
PPARg was initially identi¢ed in adipocytes and later on in
monocytes and macrophages. Resting bone marrow derived
murine macrophages were shown to express low levels of PPARg,
whereas activated peritoneal macrophages express high levels of
PPARg (Ricote et al, 1998). Synthetic PPAR ligands, but also
15d-PGJ2 have been shown to inhibit the expression of several
genes, which are upregulated during macrophage activation. In-
duction of PPARg expression in monocytes upon di¡erentiation
through macrophages has been shown by Chinetti et al (1998).
These authors demonstrated that the activity of the NF-kBp65/
RelA subunit was inhibited in macrophages. Our data strongly
indicate that the presence of monocytes is necessary for the ob-
served inhibitory e¡ects on IgE production.Whether any soluble
factors such as IL-6 are involved or whether also cell contact de-
pendent mechanisms are applicable is currently under investiga-
tion.We did not observe any signi¢cant e¡ects by PPAR ligands
in highly puri¢ed B cell cultures. PPAR-independent e¡ects of
PPAR ligands were described recently (Rossi et al, 2000; Straus
et al, 2000) and included the observation of inhibitory e¡ects on
NF-kB activation. That PPARg plays a critical role in the control
of the B cell response has been shown by Setoguchi et al (2001).
Complete elimination of a functional PPARg gene results in em-
bryonic lethality (Kubota et al, 2000), but PPARg heterozygous
knock-out mice exhibit enhanced B cell proliferative responses
and enhanced antigen-speci¢c immune response (Setoguchi et al,
2001) leading to exacerbation of antigen-induced arthritis. Re-
cently, a direct inhibitory e¡ect of PPARg ligands on the expres-
sion of IgE heavy chain germline transcripts in the human B cell
line DND39 was described (Miyazaki et al, 2002). These authors
show that induction of epsilon germline transcription was inhib-
ited by 15d-PGJ2 through suppression of phosphorylation. We
could only ¢nd a moderate IgE inhibition by PPARg ligand
using puri¢ed peripheral B cells after CD40þ IL-4 stimulation
and analysis of epsilon germline transcriptions are currently un-
derway. Taken together these studies along with our in vivo ¢nd-
ings from ovalbumin-sensitized mice suggest that PPARg plays
an important part for immunoglobulin production.This was also
supported by our ¢nding that the production of other immuno-
globulins such as IgA, IgG, and IgMwas decreased by the PPARg
ligand. IL-6 plays an important autocrine role for B cell function
(Vercelli et al, 1989) and as we determined inhibition of IL-6 pro-
duction by ciglitazone, this cytokine may play a crucial part for
our observed e¡ects.
PPARg expression is induced by IL-4 in macrophages and mi-
croglial cells. As demonstrated recently PPARg expression is in-
duced by IL-4 also in T cells (Huang et al, 1999; Kitamura et al,
2000; Cunard et al, 2002). The ¢nding that the IL-4 promoter
contains a highly conserved PPAR response elements (PPRE)
approximately 317 bp upstream of the transcription initiation site
indicates a possible autocrine loop by which PPAR expression is
controlled.The expression of PPARg in peripheral human B cells
was reported by Padilla et al (2002). These authors determined
that apoptosis induced by PPARg agonists in unstimulated cell
lines compared with controls.Whether such mechanism occur in
CD40þ IL-4-mediated cells will need to be determined. The in
vivo data from the ciglitazone-treated mice did, however, not
show reduced B cell numbers.
The physiologic relevance of our in vitro ¢ndings are under-
lined by the in vivo data showing a decreased IL-4 response and
a signi¢cantly modulated immunoglobulin response in ovalbu-
min-sensitized mice, which were fed with ciglitazone. To date,
PPARg ligands are used for the treatment of patients su¡ering
from type 2 diabetes mellitus. Recent studies have suggested ben-
e¢cial e¡ects derived from rodent models of artherosclerosis, co-
litis, arthritis, and experimental encephalitis. Our data also
contributes to possible applications of PPAR ligands in allergic
diseases, such as rhinitis, asthma, or AD.
We thank K. Anton, S. Lescau, and A. Garcia for excellent technical support.
Table II. IL-4 and IFN-c production from splenic mononuclear cells of ciglitazone and untreated mice. Experiments were per-
formed as described in Table I. Splenic mononuclear cells (106 per mL) were cultured for 48 h either unstimulated or stimulated with PMA
(20 ng per mL) and ionomycin (0.2 mM) and cytokines were determined in the supernatants by ELISA. Shown are median7SEM of the ratio
of unstimulated to PMA stimulated splenic cells
Control group Ciglitazone group
Ovalbumin^control
group
Ovalbumin^ciglitazone
group
IL-4 9.779.2 16.479.3 20.477.4a 10.179.5b
IFN-g 16037626 13227366 19087172a 13847403b
aControl versus ovalbumin^control; po0.05.
bOvalbumin^control versus ovalbumin^ciglitazone; po0.05.
Table I. E¡ect of ciglitazone treatment on immunoglobulin production in ovalbumin-sensitized mice. Mice (n¼12) were treated
with ciglitazone (7 mg per kg body weight per day) for 2 wk. Six of these mice were ovalbumin sensitized at the following weeks (weeks 2, 3,
and 4) (10 mg ovalbumin absorbed on 1.5 mg Al(OH)3), the other six mice were injected with saline. During week 6 the mice were euthanized
and serumwas obtained.Total serum IgE (ng per mL), ovalbumin-speci¢c IgG1 (mg per mL) and ovalbumin-speci¢c IgG2a production (LU per
ml) was determined by ELISA as described previously (Herz et al, 1998;Worm et al, 2001). Shown are median7SEM
Control group Ciglitazone group
Ovalbumin^control
group
Ovalbumin^ciglitazone
control group
Total IgE 14.378 10.075 32.3715a,b 8.274b
OVA-IgG1 ND ND 711.27127a 3667139b
OVA-IgG2a ND ND 36117323a 62367356b
ND, Nondetectable.
aControl versus ovalbumin^control; po0.05.
bOvalbumin^control versus ovalbumin^ciglitazone; po0.05.
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